Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds SAQsmental-behavioural-and-psychosomatic

Paeds SAQs · mental-behavioural-and-psychosomatic

Early-onset psychosis and mania — formative SAQs

Formative SAQs on running the psychosis-mania gate: organic exclusion before any psychiatric label, duration of untreated psychosis, TEOSS pharmacotherapy, distinguishing mania from chronic irritability and substance-induced states, and antipsychotic metabolic monitoring.

20 marks30 min4 min readVerification in progress

Target exams

RACP General PaediatricsMRCPCH ClinicalABP General Pediatrics
On this page
Study tools

Target exams

RACP General PaediatricsMRCPCH ClinicalABP General Pediatrics
Prompt
Early-onset psychosis and mania

SAQ 1 (10 marks)

A 15-year-old boy is brought to the emergency department after telling his mother that classmates have implanted a chip in his head. He has not slept for four nights, is guarded and frightened, and describes a voice telling him to run. His mother thinks it is "just cannabis and stress." He has smoked high-potency cannabis daily for six months. There is no fever, no fluctuating consciousness, no focal neurology and a normal physical examination, but his marks have fallen and he has lost two friendships over three months. [2] [5]

  1. State the immediate priorities in the first hour, including what must be excluded before any psychiatric label is applied. (3) [2]
  2. Outline the role of cannabis in this presentation and the evidence supporting your advice. (3) [5] [6]
  3. Describe first-line pharmacotherapy and how the TEOSS trial should inform the choice, plus the baseline and follow-up monitoring. (4) [1] [2] [4]

Model answer — SAQ 1

(1) Immediate priorities and organic exclusion (3). Safety first: assess suicide and self-harm risk with plan, intent and means, and apply means-restriction safety planning the same day; assess for acute behavioural disturbance and catatonia. Then exclude organic disease before any psychiatric label — full physical and neurological examination, full blood count, electrolytes, liver and renal function, thyroid function, inflammatory markers and a urine drug screen, with neuroimaging and an electroencephalogram if onset is acute, consciousness fluctuates, or focal neurology is present. A psychotic young person is a medical patient first and a psychiatric patient second; a collateral history from family and school is mandatory because he is an unreliable sole historian. [2]

(2) Cannabis and the evidence (3). Cannabis is a real, modifiable and dose-related risk factor for psychosis, not an aside. Moore's systematic review found cannabis use associated with a clear increase in psychotic outcomes, and Arseneault's longitudinal study showed adolescent cannabis use raised the risk of adult psychosis in a dose-related way, with earlier, more frequent and higher-potency use being worse. In this boy, daily high-potency use may have triggered or worsened the psychotic picture, so ask about potency, frequency and age of first use, counsel reduction, and arrange a period of supported abstinence and reassessment — persistent symptoms after abstinence warrant full assessment and treatment of a primary disorder. [5] [6]

(3) Pharmacotherapy, TEOSS and monitoring (4). After specialist assessment, first-line treatment for early-onset schizophrenia is an antipsychotic. The TEOSS trial compared second-generation drugs (risperidone, olanzapine) with the first-generation molindone and found efficacy was similar across groups with different side-effect burdens — so there is no clear efficacy advantage of second- over first-generation drugs, and the side-effect profile decides the choice. Risperidone or aripiprazole are common first-line options. Because duration of untreated psychosis drives long-term outcome, prompt specialist referral and early treatment are themselves the intervention. Baseline monitoring: weight, body-mass index, waist circumference, blood pressure, fasting glucose and lipids, prolactin and an electrocardiogram; then review at 4–6 weeks, 12 weeks and six-monthly, with extrapyramidal side effects, sedation and suicide risk assessed at every contact. [1] [4]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References10ShowHide
  1. [1]Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. American Journal of Psychiatry, 2008.PMID 18794207
  2. [2]McClellan J, Stock S Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 2013.PMID 23972700
  3. [3]Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Archives of General Psychiatry, 2008.PMID 18180426
  4. [4]Penttilä M, Jääskeläinen E, Hirvonen N, Isohanni M, Miettunen J Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry, 2014.PMID 25252316
  5. [5]Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet, 2007.PMID 17662880
  6. [6]Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ, 2002.PMID 12446537
  7. [7]Geller B, Luby JL, Joshi P, Wagner KD, Emslie G, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Archives of General Psychiatry, 2012.PMID 22213771
  8. [8]Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. American Journal of Psychiatry, 2006.PMID 16816222
  9. [9]Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. American Journal of Psychiatry, 2007.PMID 17898346
  10. [10]Haas M, Delbello MP, Pandina G, Kushner S, Van Hove I, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disorders, 2009.PMID 19839994
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousDisruptive mood dysregulation disorder — formative SAQsmental-behavioural-and-psychosomaticNextEmergency mental-health assessment and disposition — formative SAQsmental-behavioural-and-psychosomatic